ASH 2021 CLL In-depth

Novel Agents Lead to Changes in Therapeutic Strategies and Sequencing for CLL

Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.

Acalabrutinib Effective for Relapsed/Refractory CLL at 3 Years

The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.

Black Patients Less Likely to Receive Novel Agents as First-Line CLL Therapy

Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.

Lymphadenopathy in CLL Patients Predicts Richter’s Syndrome Risk After Ibrutinib

The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.

Ibrutinib Plus Venetoclax Produces Superior uMRD Responses in CLL

Researchers presented updated findings from the GLOW trial.

Third COVID-19 Vaccine Dose Boosts Seroconversion Rate in CLL Patients

Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.